AURA BIOSCIENCES INC. - COMMON STOCK

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

15 май 2025 09:32:51 Источник Nasdaq GlobeNewswire

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

15 май 2025 06:10:49 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

15 май 2025 06:01:00 Источник Nasdaq GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences

01 май 2025 16:01:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

02 апр 2025 07:00:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

24 мар 2025 16:01:00 Источник Nasdaq GlobeNewswire

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

24 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

03 мар 2025 07:00:00 Источник Nasdaq GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences

25 фев 2025 07:00:01 Источник Nasdaq GlobeNewswire

Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

12 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

17 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

12 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

03 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire

Aura Biosciences to Participate in Upcoming Investor Conferences

28 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

26 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

08 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

30 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

23 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

09 май 2024 07:00:01 Источник Nasdaq GlobeNewswire